TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25331981
Drug: Self-administered parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered parent training with minimal therapist contact (written material and brief weekly telephone consultations)
Study: 25331981
Drug: Self-administered parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered parent training
Study: 20969665
Drug: LGP‐HA+L (large-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGP‐HA+L (large-gel particle hyaluronic acid plus 0.3% lidocaine)
Study: 20969665
Drug: LGP‐HA (large-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGP‐HA (large-gel particle hyaluronic acid without lidocaine)
Study: 11955728
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 800 mg/day (20 milliliters po qAM)
Study: 9536950
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily for one week)
Study: 1695785
Drug: Alpha blockers
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha blockers (e.g., prazosin, terazosin)
Study: 1695785
Drug: Nonselective alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective alpha blockers (e.g., phenoxybenzamine)
Study: 30654912
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation of 4000 IU daily for three years
Study: 22105592
Drug: Metformin exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin exposure with contrast media (CM)
Study: 16365066
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (50 mg/d)
Study: 12801622
Drug: xuezhikang 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: xuezhikang 1200 mg/day (600 mg twice daily)
Study: 2865275
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (2.5 mg)
Study: 2865275
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg/kg IV bolus, maintained by 0.025 to 0.04 mg/kg/hr infusion for eight hours)
Study: 27157027
Drug: Motivational text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational text message intervention adjunct to cognitive-behavioral therapy
Study: 15925286
Drug: Impact (Japan)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Impact (Japan) supplement (1 L/d for 5 days before surgery)
Study: 15925286
Drug: Impact (Japan)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Impact (Japan) supplement
Study: 15521326
Drug: Novel controlled-release
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel controlled-release formulations of niacin based on polyethylene oxide (PEO) and hydroxypropylmethyl cellulose (HPMC) matrices.
Study: 15521326
Drug: Formulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation of interest (specific formulation not detailed).
Study: 11526359
Drug: Photopheresis (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photopheresis (5 treatments)
Study: 9232448
Drug: Birch allergen
Normalized name: sweet birch allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch allergen immunotherapy (IT)
Study: 8453021
Drug: Sublingual and
Normalized name: Buprenorphine and Naloxone Sublingual Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual and aerosolized nitroglycerin
Study: 20537815
Drug: Employment (Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Employment (Drug or Money)
Study: 20537815
Drug: Punishment (Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Punishment (Drug Only+Money Loss)
Study: 20537815
Drug: Unemployment (Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unemployment (Drug Only)
Study: 14606736
Drug: Musical motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Musical motor feedback (MMF) therapy, 15 sessions
Study: 14606736
Drug: Conventional gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gait therapy, 15 sessions
Study: 11105402
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CAI and TCL
Study: 8872686
Drug: Propofol 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.125 mg/kg injection, propofol 12.5 mcg/kg/min infusion
Study: 8872686
Drug: Propofol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.25 mg/kg injection, propofol 25 mcg/kg/min infusion
Study: 8872686
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg injection, propofol 50 mcg/kg/min infusion
Study: 8872686
Drug: Fentanyl 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.4 mcg/kg injection (positive control)
Study: 1326277
Drug: High-dose marihuana
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose marihuana (2.53% delta 9-tetrahydrocannabinol)
Study: 1326277
Drug: Low-dose marihuana
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose marihuana (1.26% delta 9-tetrahydrocannabinol)
Study: 3880992
Drug: Digoxin (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.50 mg intravenously in 20 minutes)
Study: 22974804
Drug: losmapimod 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: losmapimod 7.5 mg once daily (lower dose)
Study: 22974804
Drug: losmapimod 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: losmapimod 7.5 mg twice daily (higher dose)
Study: 19890632
Drug: Recombinant poxviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant poxviral vaccine with GM-CSF
Study: 19890632
Drug: Recombinant poxviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant poxviral vaccine without GM-CSF
Study: 19890632
Drug: Recombinant poxviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant poxviral vaccine
Study: 17917313
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment for 3 months
Study: 17917313
Drug: No CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CPAP treatment (control)
Study: 15388511
Drug: infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: infliximab 5 mg/kg every 6 weeks
Study: 10442958
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose propofol (2-2.5 mg x kg(‐1) bolus then 200 microg x kg(‐1) x min(‐1))
Study: 10442958
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose propofol (1-2.5 mg x kg(‐1) bolus then 100 microg x kg(‐1) x min(‐1))
Study: 7771914
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (0.1 mg/kg)
Study: 21415050
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 200 mg plus methotrexate (MTX)
Study: 21415050
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg plus methotrexate (MTX)
Study: 19561422
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine (Sub/MF59)
Study: 19561422
Drug: Nonadjuvanted split
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonadjuvanted split vaccine (split)
Study: 17339550
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose levels (adjusted for age, sex, smoking, previous myocardial infarction, hypertension, waist‐to‐hip ratio, creatinine, DM, and use of aspirin, beta‐blockers, or statins)
Study: 15230816
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg twice daily for 1 month, 200 microg twice daily for 5 months
Study: 15230816
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 10 mg three-times daily for 6 months
Study: 1864315
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of mifepristone (RU 486)
Study: 26038847
Drug: Rupatadine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 20 mg/day
Study: 26038847
Drug: Rupatadine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 40 mg/day
Study: 24887185
Drug: Linum usitatissimum
Normalized name: LINUM USITATISSIMUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linum usitatissimum L. (linseed) oil
Study: 17324009
Drug: Plerixafor as
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor as a single mobilising agent
Study: 17324009
Drug: Plerixafor in
Normalized name: plerixafor Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor in combination with G-CSF
Study: 17324009
Drug: Plerixafor in
Normalized name: plerixafor Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor in combination with chemotherapy
Study: 17324009
Drug: G-CSF therapy
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF therapy alone
Study: 16182156
Drug: Codeine/acetaminophen 600/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/acetaminophen 600/60 mg
Study: 11935151
Drug: ACE-inhibitors (specifically
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitors (specifically enalapril, n = 8)
Study: 11935151
Drug: ACE-inhibitors (enalapril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitors (enalapril, n = 8)
Study: 7587232
Drug: Unfractionated porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated porcine heparin (20 U/kg for ex vivo evaluation)
Study: 7587232
Drug: Unfractionated porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated porcine heparin (varying doses for in vitro evaluation)
Study: 2406328
Drug: Enprofylline 300
Normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 300 mg b.i.d.
Study: 7985256
Drug: Theophylline 300
Normalized name: theophylline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 300 mg b.i.d.
Study: 2406328
Drug: Enprofylline 450
Normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 450 mg b.i.d.
Study: 2406328
Drug: Theophylline 450
Normalized name: theophylline 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 450 mg b.i.d.
Study: 31621606
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy (OT) for ten weeks
Study: 30024661
Drug: ELF‐EMF therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELF‐EMF therapy
Study: 22920798
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) delivery of insulin lispro
Study: 22920798
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) delivery of insulin lispro
Study: 9854758
Drug: titrated-dose oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: titrated-dose oxycodone and sustained-release morphine sulfate
Study: 9854758
Drug: set-dose oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: set-dose oxycodone
Study: 28099276
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (parotid injections only)
Study: 26079801
Drug: Sufentanil Sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil Sublingual Tablet System (SSTS) 15 μg
Study: 23693018
Drug: neoadjuvant DE
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant DE combined with rh-endostatin (7.5 mg/m2, d1-d14, every 3 weeks)
Study: 23693018
Drug: neoadjuvant DE
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant DE (docetaxel: 75 mg/m2, d1, epirubicin: 75 mg/m2, d1, every 3 weeks)
Study: 15904632
Drug: Enoxaparin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.75 mg/kg intravenous bolus)
Study: 15904632
Drug: Heparin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (60 U/kg intravenous bolus)
Study: 12610035
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (1.57 mg or 45 IU on each of the 2 dosing days in part 1; 4.7 mg or 135 IU in part 2)
Study: 10498559
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (n = 55)
Study: 2006659
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (triamterene and hydrochlorothiazide)
Study: 2006659
Drug: Diuretics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics plus methyldopa
Study: 29794296
Drug: Gabapentin 1,300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1,300 mg/day
Study: 29794296
Drug: Gabapentin (1,300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,300 mg/day and 900 mg/day)
Study: 26561613
Drug: UNIMMAP (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: UNIMMAP (multiple micronutrient preparation)
Study: 20869928
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical tocotrienol
Study: 15231900
Drug: IL-8 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-8 group (antibiotic therapy when IL-8 >70 pg/mL and/or CRP >10 mg/L)
Study: 15231900
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (antibiotic therapy according to the guidelines of each center)
Study: 8133796
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (50 mg every 3 weeks for 18 months)
Study: 3628442
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg diazepam
Study: 3628442
Drug: 0.14 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.14 mg/kg diazepam
Study: 3628442
Drug: 0.21 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.21 mg/kg diazepam
Study: 29620994
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of treatment
Study: 21153933
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg 5% levobupivacaine + 0.1 mg morphine (Group M)
Study: 21153933
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg 5% levobupivacaine + 20 mcg fentanyl (Group F)
Study: 16002536
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl oestradiol (EE) with cyproterone acetate (CA)
Study: 16002536
Drug: Transdermal 17beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐oestradiol (E2) with cyproterone acetate (CA)
Study: 16002536
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone esters
Study: 10928760
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C treated group (0.2 mg/mL for five minutes)
Study: 8822681
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 60mL saline and dextrose into the knee joint followed by submaximal exercise for 3 to 4 minutes
Study: 8822681
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection of fluid, followed by submaximal exercise for 3 to 4 minutes
Study: 1424419
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg lansoprazole administered once daily for 10 days
Study: 1424419
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily for 10 days
Study: 21426372
Drug: SB-656933 400
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-656933 400 mg
Study: 21426372
Drug: SB-656933 50
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-656933 50 mg
Study: 21426372
Drug: SB-656933 150
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-656933 150 mg
Study: 19628647
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus ramipril (combination therapy group)
Study: 19628647
Drug: Ramipril alone
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril alone (monotherapy group)
Study: 16765398
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulfadoxine/pyrimethamine (single dose) and artesunate (3 daily doses of 4 mg/kg)
Study: 16765398
Drug: Amodiaquine and
Normalized name: Amodiaquine and artesunate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine and artesunate (3 daily doses)
Study: 9754844
Drug: Fluvoxamine (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (160 mg average daily dosage, highest permitted dose of 300 mg/day)
Study: 7820711
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment (Curosurf), dosage and duration not specified
Study: 7820711
Drug: Immediate response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate response to surfactant treatment
Study: 21594708
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) treatment
Study: 21900715
Drug: Induction arm
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction arm (IA): pegylated interferon-α2a 270 μg/week plus ribavirin 1,600 mg daily for 4 weeks, followed by pegylated interferon-α2a at standard dosages plus weight-based ribavirin for 8 weeks.
Study: 21900715
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy arm (SA): pegylated interferon-α2a plus weight-based ribavirin for 12 weeks.
Study: 21900715
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy arm (SA)
Study: 16273807
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments from Swedish RA registry and biologics registries (ARTIS, SSATG, STURE)
Study: 9814461
Drug: Dexamethasone treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone treatment during pregnancy
Study: 2653552
Drug: Short overall
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short overall treatment times (less than or equal to 4 weeks)
Study: 2653552
Drug: Long overall
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long overall treatment times (greater than 4 weeks)
Study: 355965
Drug: Preoperative ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative ibuprofen
Study: 29117309
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (daily capsule with 109 total colony-forming units of Bifidobacterium lactis CECT 8145, B longum CECT 7347, Lactobacillus casei CECT 9104)
Study: 29117309
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (maltodextrin-only capsules)
Study: 20737519
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Panax ginseng (G115)
Study: 20737519
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Panax ginseng (G115)
Study: 18788838
Drug: Zolmitriptan 2.5
Normalized name: zolmitriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 2.5 mg three times daily
Study: 18788838
Drug: Zolmitriptan 2.5
Normalized name: zolmitriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 2.5 mg twice daily
Study: 15882219
Drug: Sub-antimicrobial dose
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-antimicrobial dose doxycycline (SDD) 20 mg twice daily with scaling and root planing (SRP)
Study: 12851185
Drug: Weekly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly group exercise programme with ancillary home exercises
Study: 11026650
Drug: TNF‐α infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α infusion without pretreatment
Study: 11026650
Drug: TNF‐α infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α infusion after acetylsalicylic acid pretreatment
Study: 11026650
Drug: TNF‐α infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α infusion after N(G)‐monomethyl‐L‐arginine pretreatment
Study: 1880092
Drug: Amoxycillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (500 mg tds)
Study: 1880092
Drug: Amoxycillin/Clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/Clavulanic acid (Augmentin; 750 mg tds)
Study: 1880092
Drug: Intravenous Augmentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Augmentin (1.2 g 8 hourly for 3 days, followed by oral doses as above for 7 days)
Study: 31070146
Drug: Intravenous Augmentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Augmentin